Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus TRAVASOL 8 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus TRAVASOL 8 5 IN PLASTIC CONTAINER.
AMINOSYN II 15% IN PLASTIC CONTAINER vs TRAVASOL 8.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
TRAVASOL 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral nutrition.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
Intravenous administration as total parenteral nutrition: typical adult dose is 8.5% amino acid solution at 0.8-1.5 g protein/kg/day, infused continuously or cyclically.
None Documented
None Documented
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Not applicable; constituent amino acids have individual half-lives (e.g., 0.5–2 hours for most L-amino acids) but overall elimination follows zero-order kinetics during continuous infusion. Clinically, infusion rate determines steady-state concentrations.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Renal elimination of nitrogenous waste products (urea, ammonia) derived from amino acid metabolism; biliary/fecal excretion negligible. In healthy adults, >90% of infused amino nitrogen is ultimately excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution